Abiopharma

🔍 Saunders Mitchell (Executive)

Company: Atlanticus Holdings Corp (ATLC)

Report Date: 2026-03-19

Detailed Transactions and Holdings:

• Acquired 929 shares of Common Stock (Direct)
  Date: 2026-03-19 | Code: A | equity_swap_involved: 0 | shares_owned_after: 52,628.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 3,715 shares of Common Stock (Direct)
  Date: 2026-03-19 | Code: A | equity_swap_involved: 0 | shares_owned_after: 56,343.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 70 shares of Common Stock at $54.67 per share (Direct)
  Date: 2026-03-20 | Code: F | equity_swap_involved: 0 | shares_owned_after: 56,273.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Grant of restricted stock, which will vest in three substantially equal installments on March 19, 2027, March 19, 2028 and March 19, 2029.
• F2: Grant of restricted stock, which will cliff vest on March 19, 2031.
• F3: Reflects shares of Atlanticus Holdings Corporation common stock withheld to satisfy tax withholding obligations upon the vesting of the restricted stock award, based on the closing price of Atlanticus Holdings Corporation common stock on March 20, 2026.